about
Effect of grapefruit juice on the bioactivation of prasugrelEffect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalaprilGrapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjectsDrug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population.CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.Grapefruit juice inhibits the metabolic activation of clopidogrel.Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.A common missense variant of LILRB5 is associated with statin intolerance and myalgia.Implications of inter-correlation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions .Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects.Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics.Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone.Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of ClopidogrelClopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate SimvastatinSLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acidGlucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug InteractionsStereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofenItraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamideThe CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopicloneClinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation.Response to "Influence of Diabetes on Antiplatelet Drug Efficacy"Cytochrome P450 in Pharmacogenetics: An UpdateCYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or PrasugrelClopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In HumansItraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug InteractionResponse to "Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?"Placental transporter-mediated drug interactions and offspring congenital anomaliesEnantiospecific Pharmacogenomics of Fluvastatin
P50
Q35846138-EA16BAD8-8FD4-431D-8F26-B063887DD7EEQ36243667-A0E6E063-5FB8-4899-967A-859C456622BAQ36948119-A4A9A21F-F908-4216-AA10-D3444AF4238BQ37999939-E96C0811-005A-4B2C-8C1C-CDF850E38138Q38933872-18D53C7F-3FD9-4BDF-BA48-514C41EEAA08Q39869704-C282F983-208E-49BA-8E9E-E8313B30AFD4Q43272816-55DFED75-4571-47D0-B32E-23CA31255A8BQ45444562-3A6C2D59-0C3E-4DC3-A261-E01BE63550FAQ46431899-FEE7E5D7-3E09-4B4C-B8FB-EF583F100A41Q46664324-465F632B-FCD3-430A-B933-B8707EBC3B79Q46968841-FEBCAE22-A915-497F-98E6-E98ABC40FB33Q47747535-2767ED1C-97C0-4552-9FD9-3538AA392E59Q48142540-8E9CAC19-8661-4578-94B8-4076191CBCDEQ48304561-A4D41081-AC06-4A98-ACEF-F51369B71F59Q49222788-3C966361-5A6C-4B1D-AA7A-D87F2269D23CQ49487192-7A6EDD6C-DE02-4BCD-9A90-7AE1FB5ACAF4Q49685370-18ACDE94-665A-4523-9964-FA7C86C66004Q49903283-3AA78FAE-73BD-4035-9AE5-C2AA011530F4Q53086784-28604D38-56E4-490A-950B-16B71FBF390BQ53601038-A0E982C1-80D6-473B-9245-413DC8B3694DQ57825080-41D7DAAF-DE70-4241-AF98-AEE70ABC9E2EQ57825101-3AD58B7F-B7C8-4FBA-900B-E7CF2301106AQ57825102-C5F7E756-101D-4ACA-8D9D-B160A727F3B5Q57825105-CEC606E3-D8FF-47B3-9F60-5444674213F8Q57825141-3A7C56D7-BFA0-4427-A89F-D493F64AD300Q57825160-2C293279-FE6F-41DA-9DF6-2BD7A87FB808Q60449866-36749959-019B-407C-9DC0-49C07147D991Q64892381-CB2A6FE6-51EA-43F8-8E70-6D0534D566BCQ87845031-4E24B897-9184-41FA-A59F-2F9DE62FC64EQ88818047-8500FE40-5AFE-4BE7-99FC-64BBF8FE0940Q89585264-4B08E4D5-8EE8-4D24-BE01-94C65398BE2FQ90988419-4B3AE38A-4CAC-44D9-83FF-232A262C27D3Q91003627-59016F89-9AF8-41FB-BE8E-058191C61B1BQ91502233-581EF9B4-B198-4D3E-B61D-6FA14B87AB2AQ91860176-64E748E5-53C4-421C-A7EF-9A8D516B6B22Q93119620-1C3D0011-BEEB-4759-913C-951490A5AA65
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Aleksi Tornio
@ast
Aleksi Tornio
@en
Aleksi Tornio
@es
Aleksi Tornio
@nl
Aleksi Tornio
@sl
type
label
Aleksi Tornio
@ast
Aleksi Tornio
@en
Aleksi Tornio
@es
Aleksi Tornio
@nl
Aleksi Tornio
@sl
prefLabel
Aleksi Tornio
@ast
Aleksi Tornio
@en
Aleksi Tornio
@es
Aleksi Tornio
@nl
Aleksi Tornio
@sl
P106
P1153
8580743400
P21
P31
P496
0000-0001-5713-5692
P569
2000-01-01T00:00:00Z